All stock lists
Xeris Biopharma Holdings, Inc. (XERS)
United States · Delayed Price · Currency is USD
Pharmaceutical Preparations
10.14-0.05 (-0.54%)
Insider Score
––Not scored
XERS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
XERS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 92.10 M | 83.13 M | 85.81 M | 74.38 M | 71.54 M |
| Revenue Growth (YoY) | 28.74 % | — | — | — | — |
| Cost of Revenue | 12.51 M | 10.57 M | 10.95 M | 11.00 M | 11.90 M |
| Gross Profit | 79.59 M | 72.55 M | 74.86 M | 63.38 M | 59.64 M |
| SG&A Expense | 61.03 M | 53.14 M | 47.50 M | 46.46 M | 44.39 M |
| R&D Expense | 10.67 M | 8.78 M | 7.87 M | 7.48 M | 8.05 M |
| Operating Expenses | 74.42 M | 64.64 M | 58.09 M | 56.65 M | 55.16 M |
| Operating Income | 5.17 M | 7.92 M | 16.77 M | 6.73 M | 4.48 M |
| Pretax Income | -31.10 M | 2.23 M | 11.08 M | 621.00 K | -1.93 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -31.10 M | 2.23 M | 11.08 M | 621.00 K | -1.93 M |
| EPS (Basic) | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 |
| EPS (Diluted) | -0.18 | 0.01 | 0.06 | 0.00 | -0.01 |
| Shares Outstanding | 172.82 M | 170.52 M | 165.96 M | 163.65 M | 159.46 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.